- Home
- DSM vs PHAT Comparison
DSM vs PHAT Comparison
Compare DSM & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- PHAT
- Stock Information
- Founded
- DSM 1989
- PHAT 2018
- Country
- DSM United States
- PHAT United States
- Employees
- DSM N/A
- PHAT N/A
- Industry
- DSM Investment Managers
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- PHAT Health Care
- Exchange
- DSM Nasdaq
- PHAT Nasdaq
- Market Cap
- DSM 270.9M
- PHAT 289.0M
- IPO Year
- DSM N/A
- PHAT 2019
- Fundamental
- Price
- DSM $5.75
- PHAT $3.14
- Analyst Decision
- DSM
- PHAT Strong Buy
- Analyst Count
- DSM 0
- PHAT 5
- Target Price
- DSM N/A
- PHAT $17.80
- AVG Volume (30 Days)
- DSM 161.7K
- PHAT 2.2M
- Earning Date
- DSM 01-01-0001
- PHAT 05-01-2025
- Dividend Yield
- DSM 3.97%
- PHAT N/A
- EPS Growth
- DSM N/A
- PHAT N/A
- EPS
- DSM N/A
- PHAT N/A
- Revenue
- DSM N/A
- PHAT $81,859,000.00
- Revenue This Year
- DSM N/A
- PHAT $201.74
- Revenue Next Year
- DSM N/A
- PHAT $114.16
- P/E Ratio
- DSM N/A
- PHAT N/A
- Revenue Growth
- DSM N/A
- PHAT 3055.70
- 52 Week Low
- DSM $4.69
- PHAT $2.35
- 52 Week High
- DSM $6.05
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- DSM 60.00
- PHAT 40.55
- Support Level
- DSM $5.63
- PHAT $2.21
- Resistance Level
- DSM $5.74
- PHAT $4.45
- Average True Range (ATR)
- DSM 0.07
- PHAT 0.42
- MACD
- DSM 0.04
- PHAT -0.08
- Stochastic Oscillator
- DSM 94.74
- PHAT 41.52
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.